112 related articles for article (PubMed ID: 31602720)
1. Discovery and structure-activity relationship of plastoquinone analogs as anticancer agents against chronic myelogenous leukemia cells.
Ciftci HI; Bayrak N; Yıldırım H; Yıldız M; Radwan MO; Otsuka M; Fujita M; Tuyun AF
Arch Pharm (Weinheim); 2019 Dec; 352(12):e1900170. PubMed ID: 31602720
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological activity of Plastoquinone analogs as a new class of anticancer agents.
Bayrak N; Yıldırım H; Yıldız M; Radwan MO; Otsuka M; Fujita M; Tuyun AF; Ciftci HI
Bioorg Chem; 2019 Nov; 92():103255. PubMed ID: 31542717
[TBL] [Abstract][Full Text] [Related]
3. A novel series of chlorinated plastoquinone analogs: Design, synthesis, and evaluation of anticancer activity.
Bayrak N; Yıldırım H; Yıldız M; Radwan MO; Otsuka M; Fujita M; Ciftci HI; Tuyun AF
Chem Biol Drug Des; 2020 Mar; 95(3):343-354. PubMed ID: 31785034
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and investigation of the mechanism of action underlying anti-leukemic effects of the quinolinequinones as LY83583 analogs.
Ciftci HI; Bayrak N; Yıldız M; Yıldırım H; Sever B; Tateishi H; Otsuka M; Fujita M; Tuyun AF
Bioorg Chem; 2021 Sep; 114():105160. PubMed ID: 34328861
[TBL] [Abstract][Full Text] [Related]
5. A New Series of Antileukemic Agents: Design, Synthesis, In Vitro and In Silico Evaluation of Thiazole-Based ABL1 Kinase Inhibitors.
Zeytün E; Altıntop MD; Sever B; Özdemir A; Ellakwa DE; Ocak Z; Ciftci HI; Otsuka M; Fujita M; Radwan MO
Anticancer Agents Med Chem; 2021; 21(9):1099-1109. PubMed ID: 32838725
[TBL] [Abstract][Full Text] [Related]
6. Structure based design, synthesis, and evaluation of anti-CML activity of the quinolinequinones as LY83583 analogs.
Bayrak N; Ciftci HI; Yıldız M; Yıldırım H; Sever B; Tateishi H; Otsuka M; Fujita M; Tuyun AF
Chem Biol Interact; 2021 Aug; 345():109555. PubMed ID: 34146539
[TBL] [Abstract][Full Text] [Related]
7. The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities.
Ciftci HI; Ozturk SE; Ali TFS; Radwan MO; Tateishi H; Koga R; Ocak Z; Can M; Otsuka M; Fujita M
Biol Pharm Bull; 2018 Apr; 41(4):570-574. PubMed ID: 29386476
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis and Biological Evaluation of Pentacyclic Triterpene Derivatives: Optimization of Anti-ABL Kinase Activity.
I Ciftci H; O Radwan M; E Ozturk S; Ulusoy NG; Sozer E; E Ellakwa D; Ocak Z; Can M; F S Ali T; I Abd-Alla H; Yayli N; Tateishi H; Otsuka M; Fujita M
Molecules; 2019 Sep; 24(19):. PubMed ID: 31574910
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
10. Apoptotic Effects of Some Tetrahydronaphthalene Derivatives on K562 Human Chronic Myelogenous Leukemia Cell Line.
Koc A; Ozkan T; Hekmatshoar Y; Gurkan-Alp AS; Aktan F; Buyukbingol Z; Sunguroglu A; Buyukbingol E; Karabay AZ
Anticancer Agents Med Chem; 2018 Feb; 17(14):1924-1930. PubMed ID: 28403785
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel Bcr-Abl inhibitors with diacylated piperazine as the flexible linker.
Pan X; Dong J; Shi Y; Shao R; Wei F; Wang J; Zhang J
Org Biomol Chem; 2015 Jul; 13(25):7050-66. PubMed ID: 26052668
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.
Liang X; Liu X; Wang B; Zou F; Wang A; Qi S; Chen C; Zhao Z; Wang W; Qi Z; Lv F; Hu Z; Wang L; Zhang S; Liu Q; Liu J
J Med Chem; 2016 Mar; 59(5):1984-2004. PubMed ID: 26789553
[TBL] [Abstract][Full Text] [Related]
13. Determination of the Apoptotic Effect and Molecular Docking of Benzamide Derivative XT5 in K562 Cells.
Ozkan T; Hekmatshoar Y; Ertan-Bolelli T; Hidayat AN; Beksac M; Aki-Yalcin E; Yalcin I; Sunguroglu A
Anticancer Agents Med Chem; 2018; 18(11):1521-1530. PubMed ID: 29298654
[TBL] [Abstract][Full Text] [Related]
14. In Vitro and In Silico Study of Analogs of Plant Product Plastoquinone to Be Effective in Colorectal Cancer Treatment.
Ciftci H; Sever B; Ocak F; Bayrak N; Yıldız M; Yıldırım H; DeMirci H; Tateishi H; Otsuka M; Fujita M; TuYuN AF
Molecules; 2022 Jan; 27(3):. PubMed ID: 35163957
[TBL] [Abstract][Full Text] [Related]
15. Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML).
Liu F; Wang B; Wang Q; Qi Z; Chen C; Kong LL; Chen JY; Liu X; Wang A; Hu C; Wang W; Wang H; Wu F; Ruan Y; Qi S; Liu J; Zou F; Hu Z; Wang W; Wang L; Zhang S; Yun CH; Zhai Z; Liu J; Liu Q
Oncotarget; 2016 Jul; 7(29):45562-45574. PubMed ID: 27322145
[TBL] [Abstract][Full Text] [Related]
16. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
[TBL] [Abstract][Full Text] [Related]
17. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, Molecular Docking, Molecular Dynamics Studies, and Biological Evaluation of 4H-Chromone-1,2,3,4-tetrahydropyrimidine-5-carboxylate Derivatives as Potential Antileukemic Agents.
Dolatkhah Z; Javanshir S; Sadr AS; Hosseini J; Sardari S
J Chem Inf Model; 2017 Jun; 57(6):1246-1257. PubMed ID: 28524659
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells.
Gamas P; Marchetti S; Puissant A; Grosso S; Jacquel A; Colosetti P; Pasquet JM; Mahon FX; Cassuto JP; Auberger P
Leukemia; 2009 Aug; 23(8):1500-6. PubMed ID: 19340007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
